doi: 10.1161/hq1001.098463
© 2001 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Effects of Prolonged Intensive Lipid-Lowering Therapy on the Characteristics of Carotid Atherosclerotic Plaques In Vivo by MRI
A Case-Control Study
From the Division of Cardiology, Department of Medicine (X.-Q.Z., E.H.F., B.G.B.), the Diagnostic Imaging Sciences Center, Department of Radiology (C.Y., X.-J.K., K.R.M.), and the Division of Vascular Surgery, Department of Surgery (T.S.H.), University of Washington, Seattle.
Correspondence to Xue-Qiao Zhao, MD, University of Washington, Cardiology, Box 358771, 1914 N 34th St, Suite 105, Seattle, WA 98103. E-mail xueqiao{at}u.washington.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Abstract—— High-resolution magnetic resonance imaging (MRI) with flow suppression not only provides useful information on luminal and wall areas of the carotid artery but also can identify the principal tissue components of the carotid atherosclerotic plaque. The effects of intensive lipid-lowering therapy on these MRI tissue characteristics were examined in patients with coronary disease (CAD). Eight CAD patients who have been receiving intensive lipid-lowering treatment (niacin 2.5 g/d, lovastatin 40 mg/d, and colestipol 20 g/d) for 10 years in the Familial Atherosclerosis Treatment Study (FATS) follow-up were randomly selected from among 60 such treated patients. Eight CAD patients who were matched to the treated patients for age (±3 years), baseline low density lipoprotein (±5 mg/dL), and triglycerides (±50 mg/dL) but who had never been treated with lipid-lowering drugs were selected as controls. For each of these 32 carotid arteries, luminal and plaque areas were measured by planimetry, in a blinded protocol, from the magnetic resonance image that showed most plaque. Fibrous tissue, calcium, and lipid deposits were identified on the basis of established criteria. Plaque composition was estimated as a fraction of total planimetered area. Patients treated with 10-year intensive lipid-lowering therapy, compared with control subjects, had significantly lower low density lipoprotein cholesterol levels (84 versus 158 mg/dL, respectively; P<0.001) and higher high density lipoprotein cholesterol levels (51 versus 37 mg/dL, respectively; P<0.001). As a group, treated patients, compared with untreated control subjects, had a smaller core lipid area (0.7 versus 10.2 mm2, respectively; P=0.01) and lipid composition (1% versus 17%, respectively). Group differences in luminal area (55 [treated] versus 44 [control] mm2, P=NS) and plaque area (58 [treated] versus 64 [control] mm2, P=NS) tended to favor treatment. MRI appears useful for estimating carotid plaque size and composition. Hyperlipidemic CAD patients frequently (97%) have at least moderate (
40% area stenosis) carotid plaque. In this case-control study, prolonged intensive lipid-lowering therapy is associated with a markedly decreased lipid content, a characteristic of clinically stable plaques.
Key Words: MRI • atherosclerotic plaque • lipid-lowering therapy
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Pathological studies1,2 of acute coronary syndromes have shown that erosion or rupture of a single coronary plaque, with superimposed thrombosis and vasospasm, is the principal mechanism precipitating ischemia. Histological studies of these culprit lesions have shown that the majority of ruptured plaques contain a soft lipid-rich core that is covered by a thin cap of fibrous tissue infiltrated by foam cells.1–4 In the past 2 decades, numerous clinical5–7 and angiographic5 studies have demonstrated that lipid-lowering therapy is effective in the primary and secondary prevention of cardiovascular events and induces angiographic regression in
12% of coronary lesions.8 The reduction in clinical events in these trials appears to be best explained by the effects of lipid-lowering therapy on the above high-risk features of plaque morphology. A hypothesis has been proposed: Lipid-lowering therapy selectively lipid-depletes (regresses) a relatively small but dangerous subgroup of vulnerable lesions containing a large lipid core and dense clusters of intimal macrophages. These lesions are thereby effectively stabilized, and the clinical event rate is accordingly decreased.9 Although shown in experimental models, plaque lipid depletion remains to be confirmed in humans.
See cover and editorial, page 1563
Recent human and animal studies have suggested that MRI of atherosclerosis may provide information on plaque composition as well as on plaque volume.10–15 The development of high-resolution MRI technique holds great promise for the evaluation of carotid atherosclerosis in vivo.11,15 In this cross-sectional case-control study, we sought to determine, by using MRI, whether hyperlipidemic patients with coronary artery disease (CAD) treated according to the recommendations of the National Cholesterol Education Program (NCEP)16 over an extended period would have carotid plaque characteristics different from those of a comparable group of untreated CAD patients. Our findings support a major lipid-depleting effect of such therapy on the carotid plaque.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Patients
Eight male CAD patients who had been receiving intensive lipid-lowering treatment (niacin 2.5 g/d, lovastatin 40 mg/d, and colestipol 20 g/d) for an average of 10 years in the Familial Atherosclerosis Treatment Study (FATS) follow-up17 were selected at random from a group of 60 such patients and designated the treated group. All 8 patients had completed 10 years and were still active in treatment; as a group, their LDL averaged <100 mg/dL during the intensive treatment. Eight male CAD patients who were matched to the treated patients for age (±3 years), off-treatment LDL (±5 mg/dL), and triglycerides (±50 mg/dL) and who had never been treated with lipid-lowering drugs were selected as controls. The diagnosis of CAD was based on coronary angiography demonstrating at least one 50% stenosis or three 30% lesions. The 2 groups were identified before any MRI was performed.
MRI Scanning
Thirty-two carotid arteries in these 16 patients were examined. All of the images were obtained with a 1.5-T imager (SIGNA, Horizon Echo Speed 5.7, General Electric Medical Systems) with custom-made bilateral carotid phased-array coils.18 MRI time was 30 to 40 minutes per patient.
Fourteen consecutive levels (per artery) that were centered at the carotid bifurcation with 3-mm section thickness and no intersection gap and that covered 4-cm portions of the common carotid, bifurcation, and internal and external carotid arteries were scanned by using time-of-flight, T1, proton-density, and T2 weightings.
The MRI parameters used in the present study are listed in Table 1.
|
Image Analysis
The image analyses were performed with the observers blinded to patient identity, treatment group, and clinical details. Images from 5 consecutive levels centered at carotid bifurcation, at 4 magnetic resonance (MR) weightings (see Table 1), were selected for detailed image analysis because plaque is more likely to develop near the carotid bifurcation.
Visual Assessment of Disease Severity and Complexity
Lesion morphology in these 20 images was visually classified into 5 types: (1) normal, (2) diffuse concentric thickening, (3) eccentric with luminal area greater than plaque area, (4) eccentric with luminal area smaller than plaque area, and (5) total occlusion. From the series of sections in each artery, the image showing the largest plaque was selected for quantitative assessment of the luminal and plaque areas and the subregions of various plaque morphological features.
Identification of Carotid Atherosclerotic Plaque Components
The selected image from each carotid artery was traced, including the outer wall, lumen, and plaque morphological features. The latter were identified as subregions of the plaque with a relatively homogeneous gray scale for each weighting. See Figure 1 for an example of this process. MR signal intensity from 4 different MR weightings was visually identified by direct comparison with a 16-level gray scale standard along the border of each image and recorded for each feature and lumen. Carotid plaque components, including fibrous tissue, calcium, and lipid deposits, were identified on the basis of previous studies that used signal intensity variation from 4 different weightings.10,19–22 Figure 2 presents an example of histological confirmation of carotid plaque tissue components, luminal, and wall area by MRI. A detailed qualitative comparison of the relative contrast from the 4 different image weightings for 4 possible plaque tissue types is given in Table 2. Prior analyses19,22 of the tissue contrast features of human atherosclerotic plaque have shown that 4 important plaque components, ie, (1) lipid, (2) calcium, (3) fibrous tissue, and (4) lipid mixed with calcium, have statistically significant differences in their pattern of imaging contrast for the 4 weightings. However, none of the contrast weighting techniques alone can differentiate all of the tissue types; a combination of different weightings is required.
|
|
|
Quantification of Carotid Luminal and Wall Areas and Plaque Components
The arterial outer wall and luminal areas were measured by planimetry with the use of NIH Image software. MRI does not distinguish readily between the fibrous tissue imaging characteristics of plaque and those of normal arterial media. As a consequence, our estimates of "plaque" area and composition include contributions from the thin rim of normal arterial media and, in reality, reflect "plaque plus media" estimates. Carotid plaque morphological features were identified visually, traced, and classified as 1 of the 4 components above, on the basis of the contrast pattern. These features, if identified, were each planimetered for area. Plaque area and the proportions of each plaque component were calculated.
MRI examples of carotid plaque components from 2 control patients are shown in Figures 3 and 4.
|
|
Statistical Analysis
The primary question addressed in this cross-sectional study was whether CAD patients exposed to prolonged intensive lipid-lowering therapy, compared with matched but untreated patients, would demonstrate different carotid plaque composition, as identified by MRI. Unpaired 2-tailed t tests were used to compare measurements from the 2 study groups, with level of P<0.05 considered significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Patient Clinical and Lipid Characteristics
As shown in Table 3, control and treated patients were comparable in terms of CAD risk and concomitant medication. However, compared with the control group lipid profile that was obtained before the MRI study, treated patients had significantly lower average on-treatment total cholesterol levels (228±14 [control] versus 163±19 [treated] mg/dL, P<0.001) and LDL levels (157±14 [control] versus 84±14 mg/dL [treated], P<0.001) and significantly higher HDL levels (37±10 [control] versus 51±10 [treated] mg/dL, P<0.001). Triglyceride levels did not differ significantly (174±74 [control] versus 184±62 mg/dL [treated], P=0.6).
|
Interobserver Variability
Thirty-two images selected for greatest plaque size were analyzed by 2 independent observers (X.-Q.Z. and B.G.B.) for measurements of the outer arterial and luminal areas and plaque morphological composition. These measurements between the 2 observers were highly concordant. The correlation coefficients were r=0.84 (P<0.001) for the outer area measurement and 0.88 (P<0.001) for the luminal area. Estimates of lipid area were most concordant (r=0.93, P<0.001), with r=0.90 (P<0.001) for calcium. Because of its relative small proportion of plaque area, estimates for lipid mixed with calcium were not as well correlated (r=0.59, P<0.001). Because of a relatively narrow range of values for the contribution of fibrous tissue to plaque composition (50% to 90%), the estimates for the fibrous tissue were also not as well correlated (r=0.65, P<0.001).
Effects of Stenosis Severity on Plaque Tissue Characteristics
The sections selected for greatest plaque size in each carotid artery were classified into approximate tertiles of measured cross-sectional luminal area reduction: 26% to 50% (n=11), 51% to 65% (n=9), and 66% to 83% (n=12). There were no significant between-treatment group differences in this distribution.
As shown in Table 4, the carotid wall area increased significantly when luminal area reduction became more severe. A trend of decreased fibrous tissue composition and of increased calcium and lipid mixed with calcium was observed with increasing luminal area reduction. Nonsignificant difference in lipid content was seen among the 3 tertiles of luminal area reduction; however, there was substantially less lipid among treated arteries in all 3 categories.
|
Between-Group Differences in Carotid Plaque Location and Obstruction
The carotid arteries from patients treated with intensive triple lipid-lowering therapy, compared with those from the matched controls, had a nonsignificant larger luminal area (55 [treated] versus 44 [control] mm2, P=0.27), a smaller wall area (58 [treated] versus 64 [control] mm2, P=0.34), and a greater lumen/wall ratio (1.0 [treated] versus 0.7 [control], P=0.19), as presented in Table 5. The most prominent carotid lesions were located in the common carotid in 53% of cases, at the bifurcation in 34%, and in the internal carotid arteries in 13%. There was no difference between the 2 groups.
|
Between-Group Differences in Carotid Plaque Composition
Table 5 and Figure 5 demonstrate that intensive triple lipid-lowering therapy was significantly associated with less plaque lipid content (0.7 [treated] versus 10.2 [control] mm2, P=0.01) and lipid composition (1% [treated] versus 17% [control], P=0.01). The treated arteries tended to have more calcium (6.4 [treated] versus 1.8 [control] mm2, P=0.07). Fibrous tissue content, per plaque, was not significantly different between the treated and control groups (46.3 versus 49.2 mm2, respectively; P=0.57), however, its composition tended to be greater in treated than in control plaques (84% versus 77%, respectively).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Our understanding of atherosclerotic plaque development and regression is derived largely from animal experiments. Studies of the nonhuman primate by Armstrong and Megan,23,24 Clarkson at al,25 Small et al,26 and Wissler and Vesselinovitch27 have demonstrated convincing evidence that atherosclerotic plaque lipid content is depleted with plasma cholesterol reduction. When cholesterol-fed animals are changed to a vegetarian diet, plasma lipids fall quickly to 140 mg/dL, and the greatly increased arterial lipid content (principally cholesterol ester) decreases by 60% over 24 to 48 months. However, collagen content is only modestly (20%) reduced.24,25 In our case-control study, prolonged intensive lipid-lowering therapy is associated with strikingly reduced plaque lipid content (1% in treated versus 17% in control patients) and with only minor difference in fibrous tissue. Thus, the MRI-measured treatment group differences in human carotid plaque composition appear consistent with the known effects of therapy on plaque composition in nonhuman primates.
Atherosclerotic plaque characteristics play an important role in plaque instability4,28–31; the risk of plaque disruption with superimposed thrombosis is predicted by its lipid-related features,28 such as the area of the core lipid region as a percentage of total plaque area32 and foam cell cluster size in the fibrous cap and shoulder regions.2,4,28–31,33 The fibrous cap is also weakened by macrophage-associated stromelysin, one of a family of inflammatory matrix metalloproteinases.34,35
The extremely low plaque lipid composition (1%) among 8 CAD patients treated with intensive lipid-lowering therapy for 10 years was associated with a low rate (5%) of the composite end point: cardiac death or nonfatal myocardial infarction over 10 years of follow-up among the larger group of 60 patients, from whom these 8 were randomly chosen.17 This encouraging result supports the idea that prolonged intensive lipid-lowering therapy will significantly decrease lipid composition in the plaque, an effect that would predict greater plaque stability and would thus reduce clinical ischemic events. Prospective studies are presently under way in randomized controlled trials to further test the hypothesis that intensive lipid-lowering therapy depletes plaque lipid and to examine the time course of such depletion and the relationship between plaque lipid depletion and change in other plaque components or plaque size (regression).
Our understanding of human plaque composition is mainly from histological studies. The Roberts group36–40 has studied human coronary plaque composition in the spectrum of clinical atherosclerosis. Others31,41,42 have studied aortic and carotid plaques. Our assessments of carotid fibrous tissue and calcium and lipid deposits with the use of MRI in vivo are consistent with previously reported histological findings.41,42
In a coronary plaque study,37 91%, 82%, and 73% of coronary plaque area was fibrous tissue identified by histology for plaque with postmortem luminal narrowing of 26% to 50%, 51% to 75%, and 76% to 95%, respectively. In the present study, 86%, 82%, and 74% of the carotid plaque area was identified by MRI as fibrous tissue for plaques with in vivo luminal area reduction of 26% to 50%, 51% to 65%, and 66% to 83% stenosis, respectively. We saw a trend of increased calcium content with increasing luminal narrowing in carotid plaques, and the Roberts group (Kragel and colleagues36,37) has demonstrated the same phenomena in the coronary plaques. Furthermore, our measured lipid content, 17% by MRI, from the control patients was also similar to pultaceous debris plus foam cells and foam cells with lymphocytes (12% to 14% in coronary plaques by histology).36,37 Ex vivo MRI was recently found to identify lipid-rich core and fibrocellular lipid with a high level of sensitivity and specificity.43 These data suggest that carotid plaque composition may have important potential to serve as a surrogate marker for coronary plaque composition.
To study the effects of lipid-lowering therapy on human atherosclerotic plaque size and composition in vivo, an imaging technique is needed that can characterize the cross-sectional morphology and composition of the atherosclerotic arterial wall. MRI is ideal for longitudinal studies of atherosclerotic arteries because it is noninvasive and is superior to other imaging modalities in discriminating soft tissue contrast.10–14,19,20,44–46 With current technology, the carotid application illustrated in the present study appears most promising. For widespread use, the speed of these measurements and their variability must be improved. Currently under development in our laboratory is an automated MRI analysis system that should provide accurate and more reproducible quantification of arterial luminal and wall areas and of the various tissue components and that will make image analysis more objective and less tedious.
In summary, the noninvasive analysis of carotid plaque in vivo by MRI provides an opportunity for longitudinally assessing changes in atherosclerotic lesions and, in particular, their tissue composition. Such studies appear to have great potential for more meaningful subclassification of atherosclerotic plaque pathology, for risk stratification, and for elucidation of certain of the mechanisms by which effective therapies prevent ischemic events.
|
Acknowledgments |
|---|
This research is supported in part by National Institutes of Health (NIH) grants (P01 HL-30086, R01 HL-19451, and R01-49546) from the National Heart, Lung, and Blood Institute; by a grant from the John Locke, Jr, Charitable Trust; by the University of Washington Clinical Research Center (NIH RR-37); and by a grant (DK-35816) to the University of Washington Clinical Nutrition Research Unit from the National Institute of Diabetes, Digestive, and Kidney Disorders.
Received July 13, 2001; accepted August 29, 2001.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992; 326: 242–250 and 310–318.[Medline] [Order article via Infotrieve]
2.
Van der Wal AC, Becker AE, Van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994; 89: 36–44.
3.
Falk E, Shah P, Fuster V. Coronary plaque disruption. Circulation. 1995; 92: 657–671.
4.
Davis MJ. Stability and instability: two faces of coronary atherosclerosis: the Paul Dudley White Lecture 1995. Circulation. 1996; 94: 2013–2020.
5. Brown B, Zhao X-Q. Lipid-lowering therapy.In: Hennekens CH, Buring JE, Manson JE, Ridker PM, Braunwald E, eds. Clinical Trials in Cardiovascular Disease: A Companion to Braunwald’s Heart Disease. Philadelphia, Pa: WB Saunders; 1999: 199–216.
6.
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: the Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Study Group. N Engl J Med. 1998; 339: 1349–1357.
7.
Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998; 279: 1615–1622.
8. Brown BG, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990; 323: 1289–1298.[Abstract]
9.
Brown BG, Zhao X-Q, Sacco DE, Albers JJ. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 1993; 87: 1781–1791.
10.
Toussaint J, LaMuraglin G, Southern J, Fuster V, Kanton H. Magnetic resonance images lipid, fibrous, calcified, hemorrhagic, and thrombotic components of human atherosclerosis in vivo. Circulation. 1996; 94: 932–938.
11. Yuan C, Murakami J, Hayes C, Tsuruda J, Hatsukami T, Wildy K, Ferguson M, Strandness D. Phased-array magnetic resonance imaging of the carotid artery bifurcation: preliminary results in healthy volunteers and a patient with atherosclerotic disease. J Magn Reson Imaging. 1995; 5: 561–565.[Medline] [Order article via Infotrieve]
12. Gold G, Pauly J, Glover G, Moretto J, Macovski A, Herfkens R. Characterization of atherosclerosis with a 1.5-T imaging system. J Magn Reson Imaging. 1993; 3: 399–407.[Medline] [Order article via Infotrieve]
13. Martin A, Gotlieb A, Henkelman R. High resolution MR imaging of human arteries. J Magn Reson Imaging. 1995; 5: 93–100.[Medline] [Order article via Infotrieve]
14.
Mohiaddin R, Longmore D. MRI studies of atherosclerotic vascular disease: structural evaluation and physiological measurements. Br Med Bull. 1989; 45: 968–990.
15.
Yuan C, Beach KW, Smith LH Jr, Hatsukami TS. Measurement of atherosclerotic carotid plaque size in vivo using high resolution magnetic resonance imaging. Circulation. 1998; 98: 2666–2671.
16.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 1993; 269: 3015–3023.
17. Brown BG, Brockenbrough A, Zhao XQ, Dowdy AA, Monick EA, Frechette EH, Poulin DC, Rocha AL. Very intensive lipid therapy with lovastatin, niacin, and colestipol for prevention of death and myocardial infarction: a 10-year Familial Atherosclerosis Treatment Study (FATS) follow-up. Circulation. 1998; 98: 3341.
18. Hayes CE, Mathis CM, Yuan C. Surface coil phased arrays for high resolution imaging of the carotid arteries. J Magn Reson Imaging. 1996; 1: 109–112.
19. Von Ingersleben G, Schmiedl UP, Hatsukami TS, Nelson JA, Subramaniam DS, Ferguson MS, Yuan C. Characterization of atherosclerotic plaques at the carotid bifurcation: correlation of high-resolution MR imaging with histologic analysis: preliminary study. Radiographics. 1997; 17: 1417–1423.[Abstract]
20.
Yuan C, Petty C, O’Brien KD, Hatsukami TS, Eary JF, Brown BG. In vitro and in situ magnetic resonance imaging signal features of atherosclerotic plaque-associated lipids. Arterioscler Thromb Vasc Biol. 1997; 17: 1496–1503.
21.
Shinnar M, Fallon JT, Wehrli S, Levin M, Dalmacy D, Fayad ZA, Badimon JJ, Harrington M, Harrington E, Fuster V. The diagnostic accuracy of ex vivo MRI for human atherosclerotic plaque characterization. Arterioscler Thromb Vasc Biol. 1999; 19: 2756–2761.
22. Yuan C, Hatsukami TS, O’Brien K. High resolution MR imaging of atherosclerotic human coronary arteries ex vivo: evaluation of plaque tissue contrast. In: The First International Workshop on Coronary MR and CT Angiography; October 2000; Lyon, France.
23.
Armstrong ML, Megan MB. Lipid depletion in atheromatous coronary arteries in rhesus monkeys after regression diets. Circ Res. 1972; 30: 675–680.
24.
Armstrong ML, Megan MB. Arterial fibrous protein in cynomolgus monkeys after atherogenic and regression diets. Circ Res. 1975; 36: 256–261.
25. Clarkson TB, Bond MG, Bullock BC, Marzetta CA. A study of atherosclerosis regression in Macaca mulatta, IV: changes in coronary arteries from animals with atherosclerosis induced for 19 months and then regressed for 24 or 48 months at plasma cholesterol concentrations of 300 or 200 mg/dl. Exp Mol Pathol. 1981; 34: 345–368.[Medline] [Order article via Infotrieve]
26. Small DM, Bond MG, Waugh D, Prack M, Sawyer JK. Physiochemical and histological changes in the arterial wall of nonhuman primates during progression and regression of atherosclerosis. J Clin Invest. 1984; 73: 1590–1605.
27. Wissler RW, Vesselinovitch D. Can atherosclerotic plaques regress?: anatomic and biochemical evidence from nonhuman animal models. Am J Cardiol. 1990; 65: 33–40.
28. Constantinides P. Plaque hemorrhages, their genesis and their role in supra-plaque thrombosis and atherogenesis.In: Glagov S, Newman WP, Schaffer SA, eds. Pathobiology of the Human Atherosclerotic Plaque. New York, NY: Springer-Verlag; 1998: 393–411.
29. Tracey RE, Devaney K, Kissling G. Characteristics of the plaque under a coronary thrombus. Virchows Arch. 1985; 405: 411–427.[Medline] [Order article via Infotrieve]
30. Lendon CL, Davies MJ, Born GVR, Richardson PD. Atherosclerotic plaque caps are locally weakened when macrophage density is increased. Atherosclerosis. 1991; 87: 87–90.[Medline] [Order article via Infotrieve]
31.
Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes: implications for plaque rupture. Circulation. 1994; 90: 775–778.
32.
Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophages, and smooth muscle cell content. Br Heart J. 1993; 69: 377–381.
33. Richardson PD Davies MJ, Born GVR. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet. 1989; 3: 941–944.
34. Shah PK, Falk E, Badimon JJ, Levy G, Fernandez-Oritz A, Fallon J, Fuster V. Human monocyte-derived macrophages express collagenase and induce collagen breakdown in atherosclerotic fibrous caps: implication for plaque rupture. Circulation. 1993; 88 (suppl I): I-254.Abstract.
35.
Henney AM, Wakeley PR, Davies MJ, Foster K, Hembrey R, Murphy G, Humphries S. Location of stromelysin gene in atherosclerotic plaques using in-site hybridization. Proc Natl Acad Sci U S A. 1991; 88: 8154–8158.
36.
Kragel AH, Reddy SG, Wittes JT, Roberts WC. Morphometric analysis of the composition of atherosclerotic plaques in the four major epicardial coronary arteries in acute myocardial infarction and in sudden coronary death. Circulation. 1989; 80: 1747–1756.
37. Kragel AH, Reddy SG, Wittes JT, Roberts WC. Morphometric analysis of the composition of coronary arterial plaques in isolated unstable angina pectoris with pain at rest. Am J Cardiol. 1990; 66: 562–567.[Medline] [Order article via Infotrieve]
38. Dollar AL, Kragel AH, Fernicola DJ, Waclaview MA, Roberts WC. Composition of atherosclerotic plaques in coronary arteries in women less than 40 years of age with fatal coronary artery disease and implications for plaque reversibility. Am J Cardiol. 1991; 67: 1223–1227.[Medline] [Order article via Infotrieve]
39. Gertz SD, Malezadah S, Dollar Kragel AH, Roberts WC. Composition of atherosclerotic plaques in the four major epicardial coronary arteries in patients greater than or equal to 90 years of age. Am J Cardiol. 1991; 67: 1228–1233.[Medline] [Order article via Infotrieve]
40. Kragel AH, Roberts WC. Composition of atherosclerotic plaques in the coronary arteries in homozygous familial hypercholesterolemia. Am Heart J. 1991; 121: 210–211.[Medline] [Order article via Infotrieve]
41. Feeley TM, Leen EJ, Colgan MP, Moore DJ, Hourihane Do, Shanik GD. Histologic characteristics of carotid artery plaque. J Vasc Surg. 1991; 13: 719–724.[Medline] [Order article via Infotrieve]
42.
Hatsukami TS, Ferguson MS, Beach KW, Gordon D, Detmer P, Burns D, Alpers C, Strandness E. Carotid plaque morphology and clinical events. Stroke. 1997; 28: 95–100.
43. Shinnar M, Fallon JT, Wehrli S, Levin M, Dalmacy D, Fayad ZA, Badimon JJ, Harrington M, Harrington E, Fuster V. The diagnostic accuracy of ex vivo MRI for human atherosclerotic plaque characterization. Arterioscler Thromb Vasc Biol. 1999; 19: 2756–2761.
44.
Merickel MB, Berr S, Spetz K, Jackson TR, Snell J, Gillies P, Shimshick E, Hainer J, Brookeman JR, Ayers CR. Noninvasive quantitative evaluation of atherosclerosis using MRI and image analysis. Arterioscler Thromb. 1993; 13: 1180–1186.
45. Pearlman JD, Zajicek J, Merickel MB, Carman CS, Ayers CR, Brookeman JR, Brown MF. High-resolution lH NMR spectral signature from human atheroma. Magn Reson Med. 1988; 7: 262–279.[Medline] [Order article via Infotrieve]
46. Pearlman JD, Southern JF, Ackerman JL. Nuclear magnetic resonance microscopy of atheroma in human coronary arteries. Angiology. 1991; 42: 726–733.
This article has been cited by other articles:
 |
|
 |
|
  C. Oppenheim, O. Naggara, E. Touze, J.-C. Lacour, E. Schmitt, F. Bonneville, S. Crozier, E. Guegan-Massardier, E. Gerardin, X. Leclerc, et al. High-Resolution MR Imaging of the Cervical Arterial Wall: What the Radiologist Needs to Know RadioGraphics, September 1, 2009; 29(5): 1413 - 1431. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Ganz, J. E. Ho, and P. Y. Hsue Structural and functional manifestations of human atherosclerosis: do they run in parallel? Eur. Heart J., July 1, 2009; 30(13): 1556 - 1558. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Duivenvoorden, E. de Groot, B.M. Elsen, J.S. Lameris, R.J. van der Geest, E.S. Stroes, J.J.P. Kastelein, and A.J. Nederveen In Vivo Quantification of Carotid Artery Wall Dimensions: 3.0-Tesla MRI Versus B-Mode Ultrasound Imaging Circ Cardiovasc Imaging, May 1, 2009; 2(3): 235 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Stein Additional Lipid Lowering Trials Using Surrogate Measurements of Atherosclerosis by Carotid Intima-Media Thickness: More Clarity or Confusion? J. Am. Coll. Cardiol., December 16, 2008; 52(25): 2206 - 2209. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Steinberg, E. J. Eichhorn, W. E. Connor, G. A. Diamond, S. Kaul, J. A. Blake, H. R. Davis Jr., N. J. Murgolo, M. P. Graziano, T. Kaye, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med., July 31, 2008; 359(5): 529 - 530. [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. TAYLOR Given the ENHANCE trial results, ezetimibe is still unproven Cleveland Clinic Journal of Medicine, July 1, 2008; 75(7): 497 - 506. [Full Text] [PDF]
|
|
|
|
|
|
B. G. Brown and A. J. Taylor Does ENHANCE Diminish Confidence in Lowering LDL or in Ezetimibe? N. Engl. J. Med., April 3, 2008; 358(14): 1504 - 1507. [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Morrisett and K. C. Vickers Vascular Calcification in Homozygote Familial Hypercholesterolemia Arterioscler Thromb Vasc Biol, April 1, 2008; 28(4): 606 - 607. [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Wasserman, A. R. Sharrett, S. Lai, A. S. Gomes, M. Cushman, A. R. Folsom, D. E. Bild, R. A. Kronmal, S. Sinha, and D. A. Bluemke Risk Factor Associations With the Presence of a Lipid Core in Carotid Plaque of Asymptomatic Individuals Using High-Resolution MRI: The Multi-Ethnic Study of Atherosclerosis (MESA) Stroke, February 1, 2008; 39(2): 329 - 335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M S Lee and R. P Choudhury Prospects for atherosclerosis regression through increase in high-density lipoprotein and other emerging therapeutic targets Heart, May 1, 2007; 93(5): 559 - 564. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. G. Brown A Direct Comparison of Intravascular Ultrasound and Quantitative Coronary Arteriography: Implications for Measures of Atherosclerosis as Clinical Surrogates Circulation, April 10, 2007; 115(14): 1824 - 1826. [Full Text] [PDF]
|
|
|
|
|
|
B. G. Brown and X.-Q. Zhao Is Intravascular Ultrasound the Gold Standard Surrogate for Clinically Relevant Atherosclerosis Progression? J. Am. Coll. Cardiol., March 6, 2007; 49(9): 933 - 938. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. Pessanha, K. Potter, F. D. Kolodgie, A. Farb, R. Kutys, E. K. Mont, A. P. Burke, T. J. O'Leary, and R. Virmani Characterization of Intimal Changes in Coronary Artery Specimens with MR Microscopy Radiology, October 1, 2006; 241(1): 107 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Crouse III Thematic review series: Patient-Oriented Research. Imaging atherosclerosis: state of the art J. Lipid Res., August 1, 2006; 47(8): 1677 - 1699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Wilensky, H. K. Song, and V. A. Ferrari Role of magnetic resonance and intravascular magnetic resonance in the detection of vulnerable plaques. J. Am. Coll. Cardiol., April 18, 2006; 47(8 Suppl): C48 - C56. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Momiyama, R. Kato, Z. A. Fayad, N. Tanaka, H. Taniguchi, R. Ohmori, T. Kihara, A. Kameyama, K. Miyazaki, K. Kimura, et al. A Possible Association Between Coronary Plaque Instability and Complex Plaques in Abdominal Aorta Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 903 - 909. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Takaya, C. Yuan, B. Chu, T. Saam, H. Underhill, J. Cai, N. Tran, N. L. Polissar, C. Isaac, M. S. Ferguson, et al. Association Between Carotid Plaque Characteristics and Subsequent Ischemic Cerebrovascular Events: A Prospective Assessment With MRI--Initial Results Stroke, March 1, 2006; 37(3): 818 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P H Lee, S H Oh, O Y Bang, I S Joo, and K Huh Pathogenesis of deep white matter medullary infarcts: a diffusion weighted magnetic resonance imaging study J. Neurol. Neurosurg. Psychiatry, December 1, 2005; 76(12): 1659 - 1663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Raggi, A. Taylor, Z. Fayad, D. O'Leary, S. Nissen, D. Rader, and L. J. Shaw Atherosclerotic Plaque Imaging: Contemporary Role in Preventive Cardiology Arch Intern Med, November 14, 2005; 165(20): 2345 - 2353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Larose, Y. Yeghiazarians, P. Libby, E.K. Yucel, M. Aikawa, D. F. Kacher, E. Aikawa, S. Kinlay, F. J. Schoen, A. P. Selwyn, et al. Characterization of Human Atherosclerotic Plaques by Intravascular Magnetic Resonance Imaging Circulation, October 11, 2005; 112(15): 2324 - 2331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Fuster, Z. A. Fayad, P. R. Moreno, M. Poon, R. Corti, and J. J. Badimon Atherothrombosis and High-Risk Plaque: Part II: Approaches by Noninvasive Computed Tomographic/Magnetic Resonance Imaging J. Am. Coll. Cardiol., October 4, 2005; 46(7): 1209 - 1218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Higgins, S. A. Marvel, and J. D. Morrisett Quantification of Calcification in Atherosclerotic Lesions Arterioscler Thromb Vasc Biol, August 1, 2005; 25(8): 1567 - 1576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Corti, V. Fuster, Z. A. Fayad, S. G. Worthley, G. Helft, W. F. Chaplin, J. Muntwyler, J. F. Viles-Gonzalez, J. Weinberger, D. A. Smith, et al. Effects of Aggressive Versus Conventional Lipid-Lowering Therapy by Simvastatin on Human Atherosclerotic Lesions: A Prospective, Randomized, Double-Blind Trial With High-Resolution Magnetic Resonance Imaging J. Am. Coll. Cardiol., July 5, 2005; 46(1): 106 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Fuster and R. J. Kim Frontiers in Cardiovascular Magnetic Resonance Circulation, July 5, 2005; 112(1): 135 - 144. [Full Text] [PDF]
|
|
|
|
|
|
N. Takaya, C. Yuan, B. Chu, T. Saam, N. L. Polissar, G. P. Jarvik, C. Isaac, J. McDonough, C. Natiello, R. Small, et al. Presence of Intraplaque Hemorrhage Stimulates Progression of Carotid Atherosclerotic Plaques: A High-Resolution Magnetic Resonance Imaging Study Circulation, May 31, 2005; 111(21): 2768 - 2775. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Wentzel, R. Corti, Z. A. Fayad, P. Wisdom, F. Macaluso, M. O. Winkelman, V. Fuster, and J. J. Badimon Does shear stress modulate both plaque progression and regression in the thoracic aorta?: Human study using serial magnetic resonance imaging J. Am. Coll. Cardiol., March 15, 2005; 45(6): 846 - 854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Yonemura, Y. Momiyama, Z. A. Fayad, M. Ayaori, R. Ohmori, K. Higashi, T. Kihara, S. Sawada, N. Iwamoto, M. Ogura, et al. Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging J. Am. Coll. Cardiol., March 1, 2005; 45(5): 733 - 742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Nandalur, E. Baskurt, K. D. Hagspiel, C. D. Phillips, and C. M. Kramer Calcified Carotid Atherosclerotic Plaque Is Associated Less with Ischemic Symptoms Than Is Noncalcified Plaque on MDCT Am. J. Roentgenol., January 1, 2005; 184(1): 295 - 298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Pennell, U. P. Sechtem, C. B. Higgins, W. J. Manning, G. M. Pohost, F. E. Rademakers, A. C. van Rossum, L. J. Shaw, and E. K. Yucel Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report Eur. Heart J., November 1, 2004; 25(21): 1940 - 1965. [Full Text] [PDF]
|
|
|
|
|
|
C. M. Kramer, L. A. Cerilli, K. Hagspiel, J. M. DiMaria, F. H. Epstein, and J. A. Kern Magnetic Resonance Imaging Identifies the Fibrous Cap in Atherosclerotic Abdominal Aortic Aneurysm Circulation, March 2, 2004; 109(8): 1016 - 1021. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Corti, J. I. Osende, J. T. Fallon, V. Fuster, G. Mizsei, H. Jneid, S. D. Wright, W. F. Chaplin, and J. J. Badimon The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging J. Am. Coll. Cardiol., February 4, 2004; 43(3): 464 - 473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. H. Lee, O. Y. Bang, S. H. Oh, I. S. Joo, and K. Huh Subcortical White Matter Infarcts: Comparison of Superficial Perforating Artery and Internal Border-Zone Infarcts Using Diffusion-Weighted Magnetic Resonance Imaging Stroke, November 1, 2003; 34(11): 2630 - 2635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Tuzcu and P. Schoenhagen Acute coronary syndromes, plaque vulnerability,and carotid artery disease: The changing role ofatherosclerosis imaging J. Am. Coll. Cardiol., September 17, 2003; 42(6): 1033 - 1036. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Pierre-Paul and V. Gahtan Noncholesterol-Lowering Effects of Statins Vascular and Endovascular Surgery, September 1, 2003; 37(5): 301 - 313. [Abstract] [PDF]
|
|
|
|
|
|
R. Corti, V. Fuster, Z. A. Fayad, S. G. Worthley, G. Helft, D. Smith, J. Weinberger, J. Wentzel, G. Mizsei, M. Mercuri, et al. Lipid Lowering by Simvastatin Induces Regression of Human Atherosclerotic Lesions: Two Years' Follow-Up by High-Resolution Noninvasive Magnetic Resonance Imaging Circulation, December 3, 2002; 106(23): 2884 - 2887. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Adams, D. M. Simoni, C. B. Bordelon Jr, G. W. Vick III, K. T. Kimball, W. Insull Jr, and J. D. Morrisett Bilateral Symmetry of Human Carotid Artery Atherosclerosis Stroke, November 1, 2002; 33(11): 2575 - 2580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. A. Fayad, V. Fuster, K. Nikolaou, and C. Becker Computed Tomography and Magnetic Resonance Imaging for Noninvasive Coronary Angiography and Plaque Imaging: Current and Potential Future Concepts Circulation, October 8, 2002; 106(15): 2026 - 2034. [Full Text] [PDF]
|
|
|
|
|
|
B. G. Brown, M. C. Cheung, A. C. Lee, X.-Q. Zhao, and A. Chait Antioxidant Vitamins and Lipid Therapy: End of a Long Romance? Arterioscler Thromb Vasc Biol, October 1, 2002; 22(10): 1535 - 1546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Guyton Clinical Assessment of Atherosclerotic Lesions: Emerging From Angiographic Shadows Circulation, September 10, 2002; 106(11): 1308 - 1309. [Full Text] [PDF]
|
|
|
|
|
|
R. P. Choudhury, V. Fuster, J. J. Badimon, E. A. Fisher, and Z. A. Fayad MRI and Characterization of Atherosclerotic Plaque: Emerging Applications and Molecular Imaging Arterioscler Thromb Vasc Biol, July 1, 2002; 22(7): 1065 - 1074. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||